**Core Concept**
Idiopathic central precocious puberty (ICPP) is a condition where children experience early onset of puberty due to premature activation of the hypothalamic-pituitary-gonadal axis, without any identifiable cause. The treatment aims to delay or halt this process by suppressing the production of gonadotropin-releasing hormone (GnRH).

**Why the Correct Answer is Right**
The medication used in the treatment of ICPP is a GnRH agonist, which initially stimulates and then downregulates the GnRH receptors in the pituitary gland. This leads to a decrease in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a decrease in sex hormone production and a halt in pubertal development. Examples of GnRH agonists include leuprolide and triptorelin.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because GnRH antagonists, such as ganirelix, are not typically used in the treatment of ICPP. While they can suppress LH and FSH production, their use is more common in assisted reproduction.
**Option B:** This option is incorrect because anti-androgens, such as spironolactone, are not the primary treatment for ICPP. They may be used in some cases to treat symptoms of virilization, but they do not address the underlying cause of premature puberty.
**Option C:** This option is incorrect because aromatase inhibitors, such as anastrozole, are not used to treat ICPP. They work by blocking the conversion of androgens to estrogens, but they do not suppress the production of GnRH or sex hormones.

**Clinical Pearl / High-Yield Fact**
It's essential to note that GnRH agonists can initially cause a flare of sex hormone production, so it's crucial to initiate treatment with a low dose and gradually increase it to prevent this effect.

**Correct Answer: C. Leuprolide**